Register Today Menu

"On the other hand, we denounce with righteous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment, so blinded by desire, that they cannot foresee the pain and trouble that are bound to ensue; and equal blame belongs to those who fail in their duty through weakness of will, which is the same as saying through shrinking from toil and pain. These cases are perfectly simple and easy to distinguish. In a free hour, when our power of choice is untrammelled and when nothing prevents our being able to do what we like best, every pleasure is to be welcomed and every pain avoided. But in certain circumstances and owing to the claims of duty or the obligations of business it will frequently occur that pleasures have to be repudiated and annoyances accepted. The wise man therefore always holds in these matters to this principle of selection: he rejects pleasures to secure other greater pleasures, or else he endures pains to avoid worse pains."

"At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat."

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.

The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.

The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.

The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.

The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.

The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.

The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.

"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?"

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum."

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

"On the other hand, we denounce with righteous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment, so blinded by desire, that they cannot foresee the pain and trouble that are bound to ensue; and equal blame belongs to those who fail in their duty through weakness of will, which is the same as saying through shrinking from toil and pain. These cases are perfectly simple and easy to distinguish. In a free hour, when our power of choice is untrammelled and when nothing prevents our being able to do what we like best, every pleasure is to be welcomed and every pain avoided. But in certain circumstances and owing to the claims of duty or the obligations of business it will frequently occur that pleasures have to be repudiated and annoyances accepted. The wise man therefore always holds in these matters to this principle of selection: he rejects pleasures to secure other greater pleasures, or else he endures pains to avoid worse pains."

Posts list

If you are a male or female with a confirmed diagnosis of mild to moderate asthma aged between 18 and 65, then you may be eligible to participate in a study investigating a new drug being developed for the treatment of certain types of asthma.

Study Payment* £8,300 – £10,650.

Apply for this study

*Terms & Conditions apply.

Study Payment: £8300

"*" indicates required fields

Step 1 of 3 - Let's get started...

33%

This field is hidden when viewing the form

Advertising Source

Before you start your application, please agree to our data usage and suitability profiling policy, below.

Agreement

I understand the below and wish to proceed.

To enable us to make an assessment of your suitability for a Clinical Trial, we will first need to gather some personal details relating to your health. To ensure your suitability for a Clinical Trial, by ticking the checkbox you agree that the information you have provided is accurate to the best of your ability. Your personal data will be stored on our database which is only accessible by Simbec Research Ltd and our service providers. To aid in your suitability assessment, we will only share with companies that support us delivering our services. Under the current European Data Protection Laws (GDPR), you have a number of rights in relation to your personal data such as the right to access, right to rectification and right to be forgotten where appropriate. Please note: if you have not been contacted within 3 months of applying for a trial, please assume you are ineligible and that your data has been deleted from our system, if you believe you are eligible for another one of our trials, please apply again in 3 months. For more information regarding our commitment to your privacy, please read our Privacy-Policy

* indicates a required field

Study Period

Please select the period or part of the trial you wish to apply for*

Please select the period or part of the trial you wish to apply forPart A - Study payment: £8,300Part B - Study payment: £10,650

Your Details

Name*

First Last

Email*

Phone*

Gender at birth*

Please selectMaleFemale

Date of Birth*

Day12345678910111213141516171819202122232425262728293031

Month123456789101112

Year2025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968196719661965196419631962196119601959195819571956195519541953195219511950194919481947194619451944194319421941194019391938193719361935193419331932193119301929192819271926192519241923192219211920

Age range for this study is 18-65 years

This field is hidden when viewing the form

Today

MM slash DD slash YYYY

This field is hidden when viewing the form

Age

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Height*

Please select your height below4 foot 8 (142cm)4 foot 9 (145cm)4 foot 10 (147cm)4 foot 11 (150cm)5 foot (152cm)5 foot 1 (155cm)5 foot 2 (157cm)5 foot 3 (160cm)5 foot 4 (163cm)5 foot 5 (165cm)5 foot 6 (168cm)5 foot 7 (170cm)5 foot 8 (173cm)5 foot 9 (175cm)5 foot 10 (178cm)5 foot 11 (180cm)6 foot (183cm)6 foot 1 (185cm)6 foot 2 (188cm)6 foot 3 (191cm)6 foot 4 (193cm)6 foot 5 (196cm)6 foot 6 (198cm)6 foot 7 (201cm)6 foot 8 (203cm)6 foot 9 (206cm)6 foot 10 (208cm)6 foot 11 (211cm)7 foot (213cm)

Weight*

Please select your weight below7 stone, 12 lb / 49.90 kg7 stone, 13 lb / 50.35 kg8 stone, 0 lb / 50.80 kg8 stone, 1 lb / 51.26 kg8 stone, 2 lb / 51.71 kg8 stone, 3 lb / 52.16 kg8 stone, 4 lb / 52.62 kg8 stone, 5 lb / 53.07 kg8 stone, 6 lb / 53.52 kg8 stone, 7 lb / 53.98 kg8 stone, 8 lb / 54.43 kg8 stone, 9 lb / 54.88 kg8 stone, 10 lb / 55.34 kg8 stone, 11 lb / 55.79 kg8 stone, 12 lb / 56.25 kg8 stone, 13 lb / 56.70 kg9 stone, 0 lb / 57.15 kg9 stone, 1 lb / 57.61 kg9 stone, 2 lb / 58.06 kg9 stone, 3 lb / 58.51 kg9 stone, 4 lb / 58.97 kg9 stone, 5 lb / 59.42 kg9 stone, 6 lb / 59.87 kg9 stone, 7 lb / 60.33 kg9 stone, 8 lb / 60.78 kg9 stone, 9 lb / 61.23 kg9 stone, 10 lb / 61.69 kg9 stone, 11 lb / 62.14 kg9 stone, 12 lb / 62.60 kg9 stone, 13 lb / 63.05 kg10 stone, 0 lb / 63.50 kg10 stone, 1 lb / 63.96 kg10 stone, 2 lb / 64.41 kg10 stone, 3 lb / 64.86 kg10 stone, 4 lb / 65.32 kg10 stone, 5 lb / 65.77 kg10 stone, 6 lb / 66.22 kg10 stone, 7 lb / 66.68 kg10 stone, 8 lb / 67.13 kg10 stone, 9 lb / 67.59 kg10 stone, 10 lb / 68.04 kg10 stone, 11 lb / 68.49 kg10 stone, 12 lb / 68.95 kg10 stone, 13 lb / 69.40 kg11 stone, 0 lb / 69.85 kg11 stone, 1 lb / 70.31 kg11 stone, 2 lb / 70.76 kg11 stone, 3 lb / 71.21 kg11 stone, 4 lb / 71.67 kg11 stone, 5 lb / 72.12 kg11 stone, 6 lb / 72.57 kg11 stone, 7 lb / 73.03 kg11 stone, 8 lb / 73.48 kg11 stone, 9 lb / 73.94 kg11 stone, 10 lb / 74.39 kg11 stone, 11 lb / 74.84 kg11 stone, 12 lb / 75.30 kg11 stone, 13 lb / 75.75 kg12 stone, 0 lb / 76.20 kg12 stone, 1 lb / 76.66 kg12 stone, 2 lb / 77.11 kg12 stone, 3 lb / 77.56 kg12 stone, 4 lb / 78.02 kg12 stone, 5 lb / 78.47 kg12 stone, 6 lb / 78.93 kg12 stone, 7 lb / 79.38 kg12 stone, 8 lb / 79.83 kg12 stone, 9 lb / 80.29 kg12 stone, 10 lb / 80.74 kg12 stone, 11 lb / 81.19 kg12 stone, 12 lb / 81.65 kg12 stone, 13 lb / 82.10 kg13 stone, 0 lb / 82.55 kg13 stone, 1 lb / 83.01 kg13 stone, 2 lb / 83.46 kg13 stone, 3 lb / 83.91 kg13 stone, 4 lb / 84.37 kg13 stone, 5 lb / 84.82 kg13 stone, 6 lb / 85.28 kg13 stone, 7 lb / 85.73 kg13 stone, 8 lb / 86.18 kg13 stone, 9 lb / 86.64 kg13 stone, 10 lb / 87.09 kg13 stone, 11 lb / 87.54 kg13 stone, 12 lb / 88.00 kg13 stone, 13 lb / 88.45 kg14 stone, 0 lb / 88.90 kg14 stone, 1 lb / 89.36 kg14 stone, 2 lb / 89.81 kg14 stone, 3 lb / 90.26 kg14 stone, 4 lb / 90.72 kg14 stone, 5 lb / 91.17 kg14 stone, 6 lb / 91.63 kg14 stone, 7 lb / 92.08 kg14 stone, 8 lb / 92.53 kg14 stone, 9 lb / 92.99 kg14 stone, 10 lb / 93.44 kg14 stone, 11 lb / 93.89 kg14 stone, 12 lb / 94.35 kg14 stone, 13 lb / 94.80 kg15 stone, 0 lb / 95.25 kg15 stone, 1 lb / 95.71 kg15 stone, 2 lb / 96.16 kg15 stone, 3 lb / 96.62 kg15 stone, 4 lb / 97.07 kg15 stone, 5 lb / 97.52 kg15 stone, 6 lb / 97.98 kg15 stone, 7 lb / 98.43 kg15 stone, 8 lb / 98.88 kg15 stone, 9 lb / 99.34 kg15 stone, 10 lb / 99.79 kg15 stone, 11 lb / 100.24 kg15 stone, 12 lb / 100.70 kg15 stone, 13 lb / 101.15 kg16 stone, 0 lb / 101.60 kg16 stone, 1 lb / 102.06 kg16 stone, 2 lb / 102.51 kg16 stone, 3 lb / 102.97 kg16 stone, 4 lb / 103.42 kg16 stone, 5 lb / 103.87 kg16 stone, 6 lb / 104.33 kg16 stone, 7 lb / 104.77 kg16 stone, 8 lb / 105.23 kg16 stone, 9 lb / 105.68 kg16 stone, 10 lb / 106.14 kg16 stone, 11 lb / 106.59 kg16 stone, 12 lb / 107.04 kg16 stone, 13 lb / 107.5 kg17 stone, 0 lb / 107.95 kg17 stone, 1 lb / 108.4 kg17 stone, 2 lb / 108.86 kg17 stone, 3 lb / 109.31 kg17 stone, 4 lb / 109.76 kg17 stone, 5 lb / 110.22 kg17 stone, 6 lb / 110.67 kg17 stone, 7 lb / 111.13 kg17 stone, 8 lb / 111.58 kg17 stone, 9 lb / 112.03 kg17 stone, 10 lb / 112.49 kg17 stone, 11 lb / 112.94 kg17 stone, 12 lb / 113.39 kg17 stone, 13 lb / 113.85 kg18 stone, 0 lb / 114.3 kg18 stone, 1 lb / 114.75 kg18 stone, 2 lb / 115.21 kg18 stone, 3 lb / 115.66 kg18 stone, 4 lb / 116.11 kg18 stone, 5 lb / 116.57 kg18 stone, 6 lb / 117.02 kg18 stone, 7 lb / 117.48 kg18 stone, 8 lb / 117.93 kg18 stone, 9 lb / 118.38 kg18 stone, 10 lb / 118.84 kg18 stone, 11 lb / 119.29 kg18 stone, 12 lb / 119.74 kg18 stone, 13 lb / 120.2 kg19 stone, 0 lb / 120.65 kg19 stone, 1 lb / 121.1 kg19 stone, 2 lb / 121.56 kg19 stone, 3 lb / 122.01 kg19 stone, 4 lb / 122.46 kg

Your BMI

Your BMI

This field is hidden when viewing the form

BMI Calc

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

* indicates a required field

1. Do you regularly use illegal drugs?*

Yes

No

(i.e., Substances that are used for non-medicinal and leisure purposes. We test as part of the screening procedures.)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

2. Have you been diagnosed or tested positive for Coronavirus/COVID-19 within the last month?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

3. Have you received a COVID-19 vaccine?*

Yes

No

If yes, please give details of vaccine, including the date

3a. Have you received any other kind of vaccine within the last 30 days?*

Yes

No

If yes, please give details of vaccine, including the date

4. Do you have a confirmed diagnosis of mild to moderate asthma which has been diagnosed more than 12 months ago, for which you are currently taking medication to manage your asthma e.g., inhalers?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

5. Are you registered with a GP (must be a UK resident for at least 1 year)?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

6. Are you taking any prescription or repeat medication from a GP or a chemist*

Yes

No

(including inhalers, over-the-counter medications, and vitamins or supplements)

If yes, please give details*

7. Do you suffer from or ever had any other serious illnesses as diagnosed by your GP or health professional?*

Yes

No

(e.g., neurological, endocrinal, cardiovascular, pulmonary, haematological, immunologic, psychiatric, gastrointestinal, renal, hepatic and metabolic disease)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

8. Have you travelled to a country where there is a high incidence of parasitic infections e.g., Asia, sub-Saharan Africa or India in the last 6 months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

8a. Do you have any plans to travel to such countries within the next 12 months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

9. Have you completed any other studies in the last 30 days?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

10. Have you ever suffered from a serious allergic reaction or have a known severe allergy?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

11. Do you smoke or use any nicotine products (including vapes and eCigarettes)?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

11a. Have you smoked or used any nicotine products within the last 12 months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

11b. Do you have a smoking history of more than 5 pack years (1 pack year = 20 cigarettes per day for 1 year or 5 cigarettes per day for 4 years)?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

12. Have you donated blood/blood products in the last 30 days?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

12a. Have you lost more than 500 mL of blood in the last 30 days?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

13. Do you drink alcohol?*

Yes

No

13a. Do you consume more than 14 units per week?*

Yes

No

(For example, a can of beer/cider/lager is approximately 2 units)

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

14. Have you had any body piercings or tattoos in the last 3 months?*

Yes

No

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

15. Are you currently using some form of contraception?*

Sterilised (Vasectomy/tubal ligation)Oral Contraceptive PillInjectable ContraceptiveIntra-uterine device (IUD)Intrauterine hormone-releasing system (IUS)Implant/patchBarrier Method (condom etc)True AbstinenceSame Sex RelationshipPostmenopausalNone of the above

Thank you for your time and interest, but unfortunately based on your answer, you are not eligible to apply for this study.

please check out our other studies to see if you may be eligible to apply for one of those.

Study Information

Simbec-Orion Clinical Pharmacology will soon be running a two-part study to investigate the study drug, GB-0895.

The overall objectives of this study are to determine the safety, tolerability (degree to which side effects of a drug can be tolerated) and concentration in the blood of GB-0895 when GB-0895 is administered in different conditions i.e., single versus multiple doses and evaluating different dose strengths. Blood samples will be taken at set timepoints throughout each part of the study in order to measure the levels of GB-0895 and the levels of specific markers which are associated with the study drug and its’ intended effect. In the context of the whole study, we will analyse the results from each of the groups and each study part and combine this information in order to better understand how GB-0895 works in the body following assessment of different factors within each study part i.e., single versus multiple doses and different dose strengths.

GB-0895 is being developed for the treatment of certain types of asthma which is a common condition of the lungs that can cause difficulties in breathing as a result of inflammation (swelling) in the breathing tubes which carry air in and out of the lungs. Currently, there are many different treatment options available for this condition, including medicines that work in a similar way to GB-0895; however the intention of GB-0895 is to provide a treatment which may be taken less frequently than other treatments but with the same level of effectiveness.

This study will be split into two separate parts (Part A & Part B), and you will only participate in one part of the study.

Ready? Let's get started

Part A

The purpose of Part A is to evaluate the study objectives when GB-0895 is administered as a single dose at increasing dose strengths.

Part A will consist of up to 5 planned groups of up to 10 participants with mild to moderate asthma in each group who will evaluate a different dose of GB-0895 starting at the lowest dose and gradually increasing in each group. This is known as a single ascending dose (SAD) study. Each group will receive GB-0895 or a placebo (which contains no active drug) in the form of subcutaneous injection(s) which is a type of injection(s) into the tissue layer between the skin and muscle.

Stay Requirements

For all groups in Part A, you will be required to stay at the clinical unit for a maximum of 4 overnight stays for the treatment period.

If you participate in this part of the study, you will be required to stay at the Simbec-Orion clinical unit for 5 days (4 overnight stays – Day -1 to Day 4).

Visits

There are 12 return/outpatient visits (Days 5, 8, 15, 29, 60, 90, 120, 150, 180, 210, 270, 360), a telephone call assessment on Day 450, followed by a post-study follow up visit on Day 500. Therefore, you should ensure that you are able to commit to completing all visits before agreeing to participate in this study.

Each return visit will not require you to stay overnight; these visits will be day visits and will take less than a couple of hours to complete. You should ensure that you are available to complete all required visits before agreeing to participate in the study

Study Payment

If you complete this part of the study, you will receive a maximum inconvenience payment of £8300. This payment will be split into 7 parts as follows: £1000 after completion of the Day 8 visit, £1000 after completion of the Day 29 visit, £1000 after completion of the Day 90 visit, £1000 after completion of the Day 180 visit, £1000 after completion of the Day 270 visit, £1000 after completion of the Day 360 visit and a final payment of £2300 after completion of the Day 500 visit.

Screening Visit

Overnight Stay
Days: 5 (Day -1 to 4)

Return Visits
Visits: 12 (Days 5, 8, 15, 29, 60, 90, 120, 150, 180, 210, 270 & 360)

Telephone Call Assessment
Day 450

Post Study Follow Up Visit
Day 500

Apply Now. Be Amazing

Part B

The purpose of Part B is to evaluate the study objectives when GB-0895 is administered as a single dose at increasing dose strengths on two occasions (once on Day 1 and once on Day 85).

Part B will consist of up to 2 planned groups of up to 8 participants with mild to moderate asthma in each group who will evaluate a different dose based on doses which have been evaluated in Part A of the study (where single doses at different dose strengths were given). This is known as a multiple ascending dose (MAD) study. Each group will receive GB-0895 or a placebo (which contains no active drug) in the form of subcutaneous injection(s) which is a type of injection(s) into the tissue layer between the skin and muscle.

If you participate in this part of the study, you will be required to stay at the Simbec-Orion clinical unit for 5 days per dosing visit (4 overnight stays – Day -1 to Day 4 & Day 84 to Day 88), 16 return/outpatient visits (Days 5, 8, 15, 29, 60, 92, 99, 120, 150, 180, 210, 240, 270, 300, 360, 450), a telephone call assessment on Day 540 followed by a post-study follow up visit on Day 585. Therefore, you should ensure that you are able to commit to completing all visits before agreeing to participate in this study. If you complete this part of the study, you will receive a maximum inconvenience payment of £6650. This payment will be split into 6 parts as follows: £500 after completion of the Day 29 visit, £1000 after completion of the Day 120 visit, £500 after completion of the Day 210 visit, £500 after completion of the Day 360 visit, £500 after completion of the Day 450 visit and a final payment of £3650 after completion of the Day 585 visit

Stay Requirements

For all groups in Part B, you will be required to stay at the clinical unit for a maximum of 4 overnight stays for each of the treatment periods.

Visits

Each return visit will not require you to stay overnight; these visits will be day visits and will take less than a couple of hours to complete. You should ensure that you are available to complete all required visits before agreeing to participate in the study.

Study Payment

If you complete this part of the study, you will receive a maximum payment of £10,650 for the inconvenience of participating in and satisfactorily completing this part of the study including all procedures and the post-study follow up visit, along with the highest level of compliance. This payment will be split into 7 parts as follows: £1000 after completion of the Day 29 visit, £1000 after completion of the Day 92 visit, £1000 after completion of the Day 150 visit, £1000 after completion of the Day 210 visit, £1000 after completion of the Day 360 visit, £1000 after completion of the Day 450 visit and a final payment of £4650 after completion of the Day 585 visit

Screening Visit

Overnight Stay
Days: 5 (Days -1 to 4)

Return Visits
Days: 11 (Days 92, 99, 120, 150, 180, 210, 240, 270, 300, 360, & 450)

Telephone Call Assessment
Day 540

Post Study Follow Up Visit
Day 585

Apply Now. Be Amazing

1914 translation by H. Rackham

06/12/2023

“On the other hand, we denounce with righteous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment, so blinded by desire, that they cannot foresee the pain and trouble that are bound to ensue; and equal blame belongs to those who fail in their duty through […]

Read

Section 1.10.33 of “de Finibus Bonorum et Malorum”, written by Cicero in 45 BC

06/12/2023

“At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, […]

Read

News item from Simbec-Orion

06/12/2023

Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272. The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and […]

Read

Section 1.10.32 of “de Finibus Bonorum et Malorum”, written by Cicero in 45 BC

06/12/2023

“Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque […]

Read

The standard Lorem Ipsum passage, used since the 1500s

06/12/2023

“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat […]

Read

What is Lorem Ipsum?

05/12/2023

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into […]

Read